Calcipotriene and betamethosone dipropionate topical foam, 0.005%/0.064%
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for Calcipotriene and betamethosone dipropionate topical foam, 0.005%/0.064%, covering 2020-08-19 to 2020-08-19. Get the full timeline:
Most recent: Clinical Trial Update: To Study Generic Calcipotriene and Betamethasone Dipropionate Topical Foam, 0.005%/0.064%, in the Treatment of Psoriasis Vulgaris (Plaque Psoriasis). [Phase 3]